{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(3)"],"submitter":["Cooper C"],"funding":["Canadian Institutes of Health Research"],"pubmed_abstract":["<h4>Introduction</h4>The risk of poor vaccine immunogenicity and more severe influenza disease in HIV necessitate strategies to improve vaccine efficacy.<h4>Methods</h4>A randomized, multi-centered, controlled, vaccine trial with three parallel groups was conducted at 12 CIHR Canadian HIV Trials Network sites. Three dosing strategies were used in HIV infected adults (18 to 60 years): two standard doses over 28 days, two double doses over 28 days and a single standard dose of influenza vaccine, administered prior to the 2008 influenza season. A trivalent killed split non-adjuvanted influenza vaccine (Fluviral™) was used. Serum hemagglutinin inhibition (HAI) activity for the three influenza strains in the vaccine was measured to assess immunogenicity.<h4>Results</h4>297 of 298 participants received at least one injection. Baseline CD4 (median 470 cells/µL) and HIV RNA (76% of patients with viral load <50 copies/mL) were similar between groups. 89% were on HAART. The overall immunogenicity of influenza vaccine across time points and the three influenza strains assessed was poor (Range HAI ≥ 40 =  31-58%). Double dose plus double dose booster slightly increased the proportion achieving HAI titre doubling from baseline for A/Brisbane and B/Florida at weeks 4, 8 and 20 compared to standard vaccine dose. Increased immunogenicity with increased antigen dose and booster dosing was most apparent in participants with unsuppressed HIV RNA at baseline. None of 8 serious adverse events were thought to be immunization-related.<h4>Conclusion</h4>Even with increased antigen dose and booster dosing, non-adjuvanted influenza vaccine immunogenicity is poor in HIV infected individuals. Alternative influenza vaccines are required in this hyporesponsive population.<h4>Trial registration</h4>ClinicalTrials.gov NCT00764998."],"journal":["PloS one"],"pagination":["e17758"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3064575"],"repository":["biostudies-literature"],"pubmed_title":["Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults."],"pmcid":["PMC3064575"],"pubmed_authors":["Thorne A","Harris M","Halperin S","Rachlis A","Walmsley S","Zubyk W","Klein M","Kilby D","Smieja M","Haase D","Mills E","Shafran S","Seguin I","CIHR Canadian HIV Trials Network Influenza Vaccine Research Group","Markanday A","Boivin G","Singer J","Cooper C","Cohen J","Conway B"],"additional_accession":[]},"is_claimable":false,"name":"Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults.","description":"<h4>Introduction</h4>The risk of poor vaccine immunogenicity and more severe influenza disease in HIV necessitate strategies to improve vaccine efficacy.<h4>Methods</h4>A randomized, multi-centered, controlled, vaccine trial with three parallel groups was conducted at 12 CIHR Canadian HIV Trials Network sites. Three dosing strategies were used in HIV infected adults (18 to 60 years): two standard doses over 28 days, two double doses over 28 days and a single standard dose of influenza vaccine, administered prior to the 2008 influenza season. A trivalent killed split non-adjuvanted influenza vaccine (Fluviral™) was used. Serum hemagglutinin inhibition (HAI) activity for the three influenza strains in the vaccine was measured to assess immunogenicity.<h4>Results</h4>297 of 298 participants received at least one injection. Baseline CD4 (median 470 cells/µL) and HIV RNA (76% of patients with viral load <50 copies/mL) were similar between groups. 89% were on HAART. The overall immunogenicity of influenza vaccine across time points and the three influenza strains assessed was poor (Range HAI ≥ 40 =  31-58%). Double dose plus double dose booster slightly increased the proportion achieving HAI titre doubling from baseline for A/Brisbane and B/Florida at weeks 4, 8 and 20 compared to standard vaccine dose. Increased immunogenicity with increased antigen dose and booster dosing was most apparent in participants with unsuppressed HIV RNA at baseline. None of 8 serious adverse events were thought to be immunization-related.<h4>Conclusion</h4>Even with increased antigen dose and booster dosing, non-adjuvanted influenza vaccine immunogenicity is poor in HIV infected individuals. Alternative influenza vaccines are required in this hyporesponsive population.<h4>Trial registration</h4>ClinicalTrials.gov NCT00764998.","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Mar","modification":"2024-10-18T15:36:17.834Z","creation":"2019-03-26T23:12:13Z"},"accession":"S-EPMC3064575","cross_references":{"pubmed":["21512577"],"doi":["10.1371/journal.pone.0017758"]}}